Xilio Therapeutics Inc (XLO)

$0.67 +0.00 (0.47%)
Market Cap 34.77M
Revenue (ttm) 6.34M
Net Income (ttm) -58.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -918.61%
Debt to Equity Ratio 0.00
Volume 366,900
Avg Vol 685,574
Day's Range N/A - N/A
Shares Out 52.50M
Stochastic %K 37%
Beta -0.07
Analysts Sell
Price Target $2.00

Company Profile

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 524 2466
Website: xiliotx.com
Address:
828 Winter Street, Suite 300, Waltham, United States
809trader
809trader Dec. 25 at 12:48 AM
$XLO Booooooom……short interest drop big time. 🥳🥳🥳🥳🥳🥳🥳🥳🥳🥳🥳🥳🥳🥳🥳🥳
1 · Reply
RS_CAP_CA
RS_CAP_CA Dec. 24 at 4:39 PM
$OMER next runner is $XLO Guaranteed….watch! https://x.com/breadmakerray/status/1968002983729479681?s=46
1 · Reply
IceBison
IceBison Dec. 19 at 5:31 PM
$XLO does anyone have average cost over $1?
2 · Reply
janlukas
janlukas Dec. 19 at 11:36 AM
$XLO Next Drug? Possible Given the Pipeline
0 · Reply
809trader
809trader Dec. 19 at 12:01 AM
$XLO very interesting after hours trade.
1 · Reply
Wizzard88
Wizzard88 Dec. 18 at 3:17 PM
$XLO In the green market this shit bleeding !
0 · Reply
IceBison
IceBison Dec. 17 at 7:37 PM
$XLO hero or zero
1 · Reply
Wizzard88
Wizzard88 Dec. 17 at 3:22 PM
$XLO You not gonna tell me after millions of shares trade for past week this shit gonna die in abyss ?!!
1 · Reply
MrProfits5594
MrProfits5594 Dec. 16 at 11:34 PM
whats everyones PT for $XLO ?
2 · Reply
ezimon
ezimon Dec. 16 at 9:18 PM
$XLO because I don't deal in fantasy!
0 · Reply
Latest News on XLO
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Nov 13, 2025, 7:30 AM EST - 6 weeks ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript

Nov 11, 2025, 4:04 AM EST - 6 weeks ago

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Nov 7, 2025, 9:05 AM EST - 6 weeks ago

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Nov 7, 2025, 9:01 AM EST - 6 weeks ago

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 3, 2025, 4:30 PM EST - 7 weeks ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

Oct 30, 2025, 9:01 AM EDT - 2 months ago

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Oct 3, 2025, 9:00 AM EDT - 2 months ago

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

Sep 9, 2025, 7:30 AM EDT - 3 months ago

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

Aug 14, 2025, 7:30 AM EDT - 4 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 2, 2025, 4:30 PM EDT - 6 months ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

Jun 10, 2025, 4:30 PM EDT - 7 months ago

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Jun 5, 2025, 6:38 PM EDT - 7 months ago

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

Jun 2, 2025, 8:46 AM EDT - 7 months ago

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

Xilio Therapeutics Announces Proposed Public Offering

Jun 2, 2025, 6:11 AM EDT - 7 months ago

Xilio Therapeutics Announces Proposed Public Offering

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

May 31, 2025, 8:00 AM EDT - 7 months ago

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025, 7:30 AM EDT - 8 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2025, 4:30 PM EDT - 8 months ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

Apr 23, 2025, 4:30 PM EDT - 8 months ago

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 7:30 AM EDT - 10 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 4:30 PM EST - 10 months ago

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?

Feb 12, 2025, 10:44 AM EST - 11 months ago

Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Feb 12, 2025, 7:35 AM EST - 11 months ago

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Feb 12, 2025, 7:33 AM EST - 11 months ago

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

Jan 21, 2025, 5:05 PM EST - 1 year ago

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 17, 2025, 4:30 PM EST - 1 year ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Dec 19, 2024, 7:30 AM EST - 1 year ago

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

Dec 16, 2024, 7:30 AM EST - 1 year ago

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Nov 7, 2024, 9:15 AM EST - 1 year ago

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

Nov 7, 2024, 9:05 AM EST - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 30, 2024, 9:01 AM EDT - 1 year ago

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 1 year ago

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 28, 2024, 4:01 PM EDT - 1 year ago

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D.

Jun 13, 2024, 4:05 PM EDT - 1 year ago

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D.

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

May 14, 2024, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Apr 1, 2024, 4:05 PM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Mar 28, 2024, 7:05 AM EDT - 1 year ago

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GILD

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 4:01 PM EST - 1 year ago

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

Jan 31, 2024, 4:01 PM EST - 2 years ago

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

Jan 8, 2024, 7:30 AM EST - 2 years ago

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

Dec 7, 2023, 7:30 AM EST - 2 years ago

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

Nov 9, 2023, 4:01 PM EST - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

Oct 31, 2023, 9:15 AM EDT - 2 years ago

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 27, 2023, 5:02 PM EDT - 2 years ago

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D.

Sep 5, 2023, 8:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D.

Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

Sep 5, 2023, 7:30 AM EDT - 2 years ago

Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results

Aug 14, 2023, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results

Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer

Aug 3, 2023, 4:05 PM EDT - 2 years ago

Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer

809trader
809trader Dec. 25 at 12:48 AM
$XLO Booooooom……short interest drop big time. 🥳🥳🥳🥳🥳🥳🥳🥳🥳🥳🥳🥳🥳🥳🥳🥳
1 · Reply
RS_CAP_CA
RS_CAP_CA Dec. 24 at 4:39 PM
$OMER next runner is $XLO Guaranteed….watch! https://x.com/breadmakerray/status/1968002983729479681?s=46
1 · Reply
IceBison
IceBison Dec. 19 at 5:31 PM
$XLO does anyone have average cost over $1?
2 · Reply
janlukas
janlukas Dec. 19 at 11:36 AM
$XLO Next Drug? Possible Given the Pipeline
0 · Reply
809trader
809trader Dec. 19 at 12:01 AM
$XLO very interesting after hours trade.
1 · Reply
Wizzard88
Wizzard88 Dec. 18 at 3:17 PM
$XLO In the green market this shit bleeding !
0 · Reply
IceBison
IceBison Dec. 17 at 7:37 PM
$XLO hero or zero
1 · Reply
Wizzard88
Wizzard88 Dec. 17 at 3:22 PM
$XLO You not gonna tell me after millions of shares trade for past week this shit gonna die in abyss ?!!
1 · Reply
MrProfits5594
MrProfits5594 Dec. 16 at 11:34 PM
whats everyones PT for $XLO ?
2 · Reply
ezimon
ezimon Dec. 16 at 9:18 PM
$XLO because I don't deal in fantasy!
0 · Reply
Jtlo
Jtlo Dec. 16 at 8:50 PM
$XLO why can’t it also have option C Be compliant and not be subjected to OTC or RS? Why don’t you lay out all potential options ?
0 · Reply
ezimon
ezimon Dec. 16 at 5:58 PM
$XLO not insinuating anything I call it out straight. It will either trade OTC or it'll be a RS pick your preferred way to lose money.
0 · Reply
Jtlo
Jtlo Dec. 16 at 2:17 AM
$XLO why are you insinuating they will for sure head to otc?
1 · Reply
Wizzard88
Wizzard88 Dec. 16 at 1:28 AM
$XLO How on Robinhood it’s 0.65 but here is 0.69 ??!!!
0 · Reply
ezimon
ezimon Dec. 15 at 11:52 PM
$XLO already explained it a million times, read it. What is your price for XLO for when they take it OTC?
1 · Reply
Jtlo
Jtlo Dec. 15 at 9:04 PM
$XLO why do you keep saying it will inevitably delist?
1 · Reply
LabPsycho
LabPsycho Dec. 15 at 6:25 PM
$XLO Will it make it down to the 50's as predicted by EOY?
0 · Reply
Wizzard88
Wizzard88 Dec. 15 at 5:45 PM
$XLO Bruuuh wtf happening today ??
0 · Reply
809trader
809trader Dec. 15 at 4:49 PM
$XLO got another 20k shares at 0.64 LFG 🥳🥳🥳
0 · Reply
ezimon
ezimon Dec. 15 at 4:06 PM
$XLO answer the question, where do you see the price heading to once its delisted in March? We can philosophise about existence and vapours later. Any company that is forced to delist as XLO will have to loses 90% or more.
0 · Reply
LesterDiamond99
LesterDiamond99 Dec. 15 at 4:02 PM
$XLO Stop loss hit average.. Adios..No interest in being a gross baggie.
1 · Reply
Jtlo
Jtlo Dec. 15 at 3:56 PM
$XLO how does that stop the price 90 percent from where it’s today? Delisting doesn’t mean it evaporates their cash on hand and assets
0 · Reply